Targeting more than one opioid receptor type simultaneously may have analgesic advantages in reducing side-effects. We have evaluated the mixed μ opioid receptor agonist/ δ opioid receptor antagonist UFP-505 in vitro and in vivo.
Introduction
Opioids have been the main treatment option for pain for centuries, but their use is associated with a number of troublesome side effects, including respiratory depression, constipation, immune suppression, physical dependence and tolerance (Dietis et al., 2011; Sehgal et al., 2013) . Analgesic tolerance is a long-term process, which is distinct to the rapid process of desensitization that arises from chronic administration of opioids (Dang and Christie, 2012) . When analgesic tolerance occurs, the patient requires increasingly higher doses of the drug in order to achieve adequate analgesia. As these higher doses result in increased side effects, including tolerance itself, it is easy to appreciate that tolerance drives an inevitable vicious clinical circle of increasing doses and increased side effects, which is the end result of chronic opioid use (Dietis et al., 2009) . Clinically, an increase in opioid analgesia can be achieved by switching opioid or adding an adjuvant, and the World Health Organization analgesic ladder describes this from a practical standpoint. However, a short-term increase in analgesia does not attenuate the development of tolerance, and therefore, a reduction in the degree of analgesia achieved is inevitable. Therefore, reducing the propensity for tolerance in novel opioids is an efficient strategy for providing adequate analgesia without detrimental dose-escalation.
Opioid receptors are members of a large family comprising the μ, δ, κ and the 'opioid-like' nociceptin/orphanin FQ receptor (NOP; Lambert, 2008; Dietis et al., 2011; Toll et al., 2018) . Almost all clinically available (and pharmaceutical developed) opioid analgesics target mainly the μ receptors, although there is current evidence for constitutive interactions among receptor subtypes (dimerization) that might change the way we think about the drug-target relationship of opioids (Gupta et al., 2006) . With relevance to our study, the most functionally important interaction of opioid receptors occurs between the μ and δ receptors (Law et al., 2005) . Gomes et al. (2000) provided evidence that μ-δ receptor dimers possess functional and ligand binding synergy, whereas George et al. (2000) showed a distinct binding profile of opioid ligands at μ-δ receptor dimers. More interestingly, however, a number of earlier studies in rodents have shown that when δ receptors are blocked by an antagonist (Abdelhamid et al., 1991; Hepburn et al., 1997) or the gene is knocked out (Zhu et al., 1999) or knocked down (Kest et al., 1996) , or the gene for the endogenous δ receptor agonist enkephalin is knocked out (Nitsche et al., 2002) , then tolerance to morphine is reduced.
From a drug development perspective, it is preferable to use a single molecule to simultaneously target the μ and δ receptors, rather than co-administering two separate drugs, both from a pharmacokinetic point of view and reduced drug interactions. For this purpose, two chemical types of opioids can be considered: bifunctional opioids (e.g. opioids that have two distinct binding properties) and bivalent opioids (e.g. opioids that possess two distinct pharmacophores in their structure) (Dietis et al., 2009) . Although these two types of 'dual' opioids have been well described in the literature during the last decade, their differentiation in terms of advantages in chemical design or molecular efficacy is not yet clear.
Our group has used the bifunctional opioid H-Dmt-TicGly-NH-Bzl (UFP-505) as a prototype μ receptor agonist and δ receptor antagonist (Balboni et al., 2010; Dietis et al., 2012) and hypothesized that this opioid ligand will produce antinociceptive actions in vivo with reduced analgesic tolerance liability. Here, we present our data from relevant in vivo assays on the tolerance, as well as new data on this ligand's effects on opioid receptor density and trafficking from assays in vitro, at recombinant μ and δ receptors and at μ /δ double expression receptor systems, and ex vivo, using rat tissues.
Methods
Additional information for the materials used can be found in the Supporting Information.
Cell culture
CHO cells stably expressing a single type of human opioid receptor (μ receptors, hMOP and δ receptors, hDOP) and cells with high expression of human δ receptors (CHO hDOP/high ) were grown as described previously (Dietis et al., 2012) . Stock cultures were supplemented with 200 μg·mL À1 geneticin (G418), for CHO hMOP , CHO hDOP and CHO hDOP/high cells, and with additional 200 μg·mL À1 hygromycin B for the novel CHO hMOP/hDOP cell line (see below). Cell cultures were kept at 37°C in 5% CO 2 /humidified air and subcultured as required using trypsin/EDTA. Cells were used for experimentation as they approached confluence and were selection agent free.
Novel cell line stably expressing human μ and δ receptors
A novel CHO cell line stably expressing the human μ and δ receptors (CHO hMOP/hDOP ) was produced by transfecting geneticin-resistant CHO hMOP cells with human δ receptor cDNA in a hygromycin B-selectable vector (pcDNA3. 1Hygro(+)/OPRD1; S&T Missouri University, USA) and selected with 800 μg·mL À1 hygromycin B and 500 μg·mL À1 geneticin (GIBCO, UK). Initially, the transfection of human δ receptors in CHO hMOP cells produced a polyclonal mixture which was further subcloned producing a final number of 30 CHO hMOP/hDOP clones. To narrow the selection for the appropriate monoclonal cell batch, all clones were screened by qRT-PCR and their μ and δ receptor mRNA expression levels were determined. The top three clones that showed the highest transfection efficiency were used in radioligand binding assays to determine receptor protein expression. One clone was selected for use, and binding data are described in the Results section. Cell culturing of CHO hMOP/hDOP cells was as described above with double selection pressure.
Saturation-binding assay to determine receptor density
Membrane protein from CHO cells (70-100 μg; prepared as described in the Supporting Information) was incubated in 0. In some experiments (as noted in Results), full saturation analysis was performed, and in others, a saturating radioligand concentration was used. Non-specific binding (NSB) was defined in the presence of 10 μM naloxone.
Reactions were terminated and bound/free radioactivity were separated by vacuum filtration through polyethyleniminesoaked (0.5%) Whatman GF/B filters, using a Brandel harvester. Bound radioactivity was determined after 8 h extraction in ScintisafeGel (Wallac, Loughborough, UK) using liquid scintillation spectroscopy.
Displacement binding assay to determine ligand selectivity and binding affinity
Membrane protein (70-100 μg) was incubated. as in the saturation assays, but containing~1 nM [ 3 H]-DPN and varying concentrations (1 pM to 10 μM) of a range of displacer ligands. NSB was defined in the presence of 10 μM naloxone. Assay incubation time, reaction termination and bound radioactivity were the same as in the saturation assay.
GTPγ 35 S assay to determine ligand functional activity
Membrane protein (70-100 μg) was incubated in 0.5 mL volume of 50 mM Tris, 0.2 mM EGTA, 1 mM MgCl 2 -6H 2 O, 100 mM NaCl, pH 7.4 supplemented with 0.1% BSA, 0.15 mM bacitracin, GDP (33 μM) and~150 pM GTPγ 35 S with gentle shaking for 1 h at 30°C. NSB was determined in the presence of non-radiolabelled 10 μM GTPγS. Reactions were terminated by vacuum filtration through dry Whatman GF/B filters, using a Brandel harvester. Bound radioactivity was determined as in the saturation assays. 
Inhibition of forskolin-stimulated cAMP formation
CHO whole-cell suspensions were incubated in 300 μL Krebs/HEPES buffer (143 mM NaCl, 4.7 mM KCl, 2.6 mM CaCl 2 , H] cAMP using a binding protein extracted from bovine adrenal glands, as described previously (Kitayama et al., 2007) . Bound and free radioactivity were separated by the addition of 250 μL of charcoal mixture (250 mg charcoal, 100 mg BSA per 25 mL solution, 50 mM Tris-HCl and 4 mM EDTA buffer at pH 7.4). Each tube was allowed to stand for 1 min before centrifugation at 12 000× g in a Sarstedt microfuge at room temperature. The supernatant (200 μL) was taken and mixed with 1 mL of Optiphase Hi-Safe scintillation liquid, and radioactivity was counted using liquid scintillation spectroscopy.
Receptor internalization and receptor desensitization assays
For the internalization study, cells (grown in large T175 flasks) were incubated with appropriate concentration of a given ligand in 20 mL of fresh culture medium for an appropriate time according to the experiment and as described in the Results section. Adherent cells were then washed three times at 4°C with harvest buffer (containing 0.9% saline, 0.02% EDTA, 10 mM HEPES, pH of 7.4) to remove any receptorbound ligand, before harvesting. Membranes were prepared as previously described (Dietis et al., 2012) , washing three times with buffer prior to three centrifugations at 1600× g and three centrifugations at 14 000× g, with subsequent removal of supernatant and resuspension of the pellet, in order to ensure that all desensitizing ligand is washed off. Then a saturation binding assay was performed as described above. For receptor internalization, CHO hMOP cells where treated with 10 μM of morphine, EM1 or fentanyl and CHO hDOP with 10 μM DPDPE, as reference compounds with the maximum concentration used in these experiments, as well as with various concentrations of UFP-505 (1 nM-10 μM) for CHO hMOP or 10 μM for CHO hDOP . For the desensitization studies, cells were incubated for 1 h (chosen as the most appropriate for tolerance-related desensitization; based on Williams et al., 2013) with an appropriate ligand at various concentrations (1 pM to 10 μM), and membranes were prepared as in the internalization study. A GTPγ 35 S assay was then performed as described above.
Arrestin assay
The PathHunter® eXpress CHO-K1 pre-validated cell lines were used (DiscoveRx, Birmingham, UK), expressing human μ or δ receptors and β-arrestin-2, supplied in an optimized cell culture medium. (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Healthy male Wistar rats (strain code 003, albino, 200-250 g; Charles Rivers Laboratories, Wilmington, MA, USA) were used in the tail-flick (TF) antinociception assay and healthy male Sprague-Dawley rats (280-300 g; Harlan, Varese, Italy) were used in the paw pressure (PP) and rotarod assays. Before any surgical or experimental procedures, all animals were housed in groups of two to three under standard controlled conditions (22 ± 1°C, 12 h light/dark cycle) with food and water ad libitum for at least 5 days. Animal weight and visible behavioural changes were monitored prior, during and after each experiment. All animals were used at least 1-week after their arrival in the lab. After surgery and during experiments, all animals were housed singly.
Intrathecal surgery
We initially used an intrathecal (i.t.) catheterization protocol for animals used in the acute TF test, but it was not possible to retain the catheters on these animals for long-term exposure (data not shown). We therefore elected to use an alternative catheterization strategy for the rest of the tests used (rotarod and PP). Below, we describe both protocols used. For the TF test, animals were anaesthetized by i.p. ketamine and xylazine (115 + 2 mg·kg À1 ; Farmaceutici Gellini, Aprilia, Italy, and Bayer, Milan, Italy), and a modification of the Storkson method of i.t. catheterization was applied (Storkson et al., 1996) at the lumbar region of the spinal cord (between L5 and L6; Supporting Information Figure S1 ). After surgery, the correct catheter positioning was assessed by lidocaine administration (15 μL, 20 mg·mL À1 , i.t.) followed by saline (10 μL, i.t.) and subsequent loss of motor control of the rear limbs within 15 s lasting for 20-30 min. One animal that did not pass this lidocaine test was excluded from the study.
The animals used in the rotarod and PP assays were anaesthetized with 2% isoflurane and the i.t. catheter was surgically implanted according to the method of Yaksh and Rudy (1976) . Rats were shaved on the back of the neck and placed in the stereotaxic frame with the head securely held between ear bars. The skin over the nap of the neck was cleaned with ethyl alcohol and incised for 1 cm. The muscle on either side of the external occipital crest was detached and retracted to expose about 3-4 mm 2 of the atlanto-occipital membrane.
The membrane was incised by a needle, which led to the escape of cerebrospinal fluid. The caudal edge of the cut was lifted, and about 7.0 cm of 28 g polyurethane catheter (0.36 mm outer diameter; 0.18 mm inner diameter; Alzet, USA) was gently inserted into the i.t. space in the midline, dorsal to the spinal cord until the lumbar enlargement. The exit end of the catheter was connected to 4.0 cm polyurethane (0.84 mm outer diameter; 0.36 mm inner diameter) and was taken out through the skin, flushed with saline solution, sealed and securely fixed on the back of the head with a silk suture. The incision site in the skin was closed with polyamide sutures and the animals allowed to recover for 24 h before the study began. The evaluation of potential motor dysfunctions induced by the surgery was investigated using a rotarod test. Any animals displaying motor disabilities (approximately 10%) were excluded from the PP behavioural measurements.
Tail-flick test
Animals were submitted to the TF test (15 s cut-off time) prior to acute i.t. treatment of varying drug concentrations in order to determine their nociceptive threshold (basal latency) and after i.t. administration of drugs at times T = 15, 30, 60, 90 and 120 min to determine treatment latency. The control group animals were treated with sterile saline (20 μL) whereas the treatment group animals were treated with 10 μL (i.t.) of UFP-505 followed by administration of sterile saline (10 μL, i.t.). Morphine was also used as a reference compound in a separate animal group, in a protocol similar to the treatment group.
Rotarod test
The rotarod apparatus (Ugo Basile, Varese, Italy) was consisted of a base platform and a rotating rod with a diameter of 6 cm and a non-slippery surface. The rod, 36 cm in length, was placed at a height of 25 cm from the base and was divided into four equal sections by five disks. Thus, up to four rats were tested simultaneously on the apparatus, with a rod-rotating speed of 10 r.p.m. The integrity of motor coordination was assessed on the basis of the number of falls from the rod during 60 s in acute protocol and 120 s during the repeated one. The test was stopped after a maximum of six falls.
Paw pressure test
The mechanical nociceptive threshold in the rat was determined with the PP test (Ugo Basile, Varese, Italy), according to the method described by Leighton et al. (1988) . A constantly increasing mechanical pressure was applied to the animal's paw, until occurrence of vocalization or withdrawal reflex, while the rats were lightly restrained. Vocalization or withdrawal reflex threshold levels were expressed in grams of the applied pressure. Animals with basal threshold below 40 g or above 75 g were excluded prior to treatment. Measurements were performed after acute i.t. injection of 0.3-30 nmol UFP-505 (10 μL). Antinociception was measured at 15, 30, 45 and 60 min after administration with a PP test. Chronic experiments (8 days) involved in i.t. daily injection of 10 nmol UFP-505 or 3 nmol morphine (in 10 μL), and antinociception in PP (along with motor coordination using a rotarod; as described above) was evaluated every day at 30 min after administration. The cut-off threshold for treated animals in this assay was 150 g. Assessments of PP and motor coordination were performed independently of each other.
Tissue removal
Animals used in the TF test were killed by decapitation immediately after the end of each experiment, and their spinal cord tissue and cerebral cortex were isolated while on ice. Tissues were stored at À80°C and used later for membrane preparation as described above. Part of the tissues scheduled for later PCR analysis were first treated with RNAlater® solution (AM7020, Applied Biosystems, USA) then stored at À20°C for 2 days and finally stored at À80°C for 3 days.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as mean ± SEM from (n) experiments, as shown in the Figure and Table legends . Concentration-response curves were analysed by nonlinear regression using GraphPad Prism V5.0 software (San Diego, CA, USA). In saturation-binding assays, the receptor density (B max ) and radioligand equilibrium dissociation constant (pK d ) were obtained from saturation-binding isotherms and semi-log transformations of specific binding data. In displacement binding assays, 50% displacement of specific binding was corrected for the competing mass of radiolabel, and the pK i values were obtained from displacement curves, and values were determined using nonlinear regression, corrected using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) performed using GraphPad Prism V5.0 software. Some data were analysed using 'Origin 9' software. Student's t-test and ANOVA with post hoc testing (Bonferroni) as required were used, as described in the Table and Figure legends (significance set at P < 0.05).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017) .
Results

In vitro characterization of UFP-505
In part of the present study, we have used δ receptorexpressing cells with receptor density ( Figure 1A left 1.8 pmol mg·protein À1 ),~1.8 higher than the reported value in Dietis et al. (2012) . In membranes prepared from these high-δ receptor expressing cells, we found significant but low partial agonist activity for UFP-505 in a GTPγ The maximum stimulation (E max ) achieved by UFP-505 binding was higher than basal levels (unstimulated), but less than that of DPDPE. *P < 0.05; Student's t-test (B) Effect of UFP-505 and reference agonists (DPDPE; 10 μM and EM1; 1 μM) on forskolin-stimulated cAMP formation in CHO hMOP and CHO hDOP (lower expression) cells. All data are presented as mean ± SEM fold increase of basal stimulation (n = 5-6). Percentage inhibition of cAMP is shown in parenthesis. Both DPDPE and EM1 produced a significant inhibition compared to forskolin (P < 0.05, one-way ANOVA with Bonferroni correction).
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(pEC 50 ; 8.54 ± 0.28) was significantly higher than that of DPDPE (7.68 ± 0.20) in membranes from these cells. Downstream from G-protein activation, the cAMP formation stimulated by forskolin, in CHO hMOP cells was inhibited by both 1 μM EM1 and 10 μM UFP-505, as shown in Figure 1B . There was no significant difference between the inhibition of cAMP formation caused by EM1 and UFP-505, indicating that UFP-505 behaves as a full agonist in this downstreamamplified assay. In CHO hDOP cells, 10 μΜ DPDPE inhibited forskolin-stimulated cAMP formation as expected for a full agonist at δ receptors ( Figure 1B) . However, the addition of 10μΜ UFP-505 resulted in a small, but significant, inhibition of forskolin-stimulated cAMP (α 0.23 relative to DPDPE), again suggesting that UFP-505 behaves as a low-efficacy, partial agonist at δ receptors in this highly amplified assay. This is an important point in discussing the behaviour of the ligand in vivo at target 'sites' with higher expression.
In vitro receptor internalization
Next, we examined the effects of UFP-505 on opioid receptor turnover. Pretreatment of CHO hMOP cells with 10 μΜ UFP-505 induced a significant loss of surface μ receptors (62%) compared to the non-treated cells (Figure 2A ). In the same assay, pretreatment with 10 μM EM1 or fentanyl also induced significant μ receptor internalization (~50% and~25%, respectively), whereas morphine was ineffective. To determine whether time of ligand pretreatment had an effect on the reduction of MOP receptor density, binding assays with saturating radioligand concentrations were performed after pretreatment of CHO hMOP cells with 10 μΜ UFP-505 for 1 and 24 h. Pretreatment with UFP-505 (control B max 457 ± 86) for 24 h induced internalization of μ receptors (B max 166 ± 15), comparable to the effects of pretreatment for 1 h (B max 108 ± 23). These two B max values were not different ( one-way ANOVA with Bonferroni correction).
The decrease in μ receptor density induced by UFP-505 was concentration-dependent, as shown in Figure 2B . UFP-505 induced a significant internalization of μ receptors at 10 and 1 μΜ compared to the control (untreated), with a pEC 50 of 6.62. This is similar with the pEC 50 produced from GTPγ 35 S binding (6.37) but lower than the pK i of UFP-505 binding (7.79) as shown in previously published data (Dietis et al., 2012) . Interestingly, in CHO hDOP cells ( Figure 2C ; B max~1 000-fmol·mg À1 protein) where UFP-505 behaves as a low-efficacy partial agonist, 10 μM of UFP-505 induced extensive internalization of δ receptors (~86%), as did the δ receptor full agonist DPDPE at 10 μM (~80%). The unexpectedly extensive δ receptor internalization by UFP-505, based on its weak intrinsic activity, raised an initial concern that the reduction seen in this assay could be an artefact, possibly due to an incomplete wash-off of the desensitizing challenge. In order to exclude this possibility, full [ 3 H]-DPN saturation curves were produced from CHO hMOP and CHO hDOP cells pretreated with 10 μΜ UFP-505 after wash off and the pK d was calculated (Figure 3 ). Representative saturation curves are shown here, from a series of five independent experiments performed after pretreatment with 10 μΜ fentanyl in CHO hMOP cells ( Figure 3B ) and 10 μΜ UFP-505 ( Figure 3C ). The pK d of the curves produced were not different from the control ( Figure 3G ), confirming that the reduced radioligand binding shown in the internalization assays and interpreted as a reduction in the B max is attributed solely to the internalization of the receptors and not to the presence of residual UFP-505 in the assay. Similarly, representative saturation curves from CHO hDOP cells (from n = 5) after pretreatment with 10 μΜ DPDPE ( Figure 3E ) and 10 μΜ UFP-505 ( Figure 3F ) are also shown here, and the resulting pK d of the curves from all pretreatment groups did not differ from the control.
Arrestin recruitment
As recruitment of arrestin is a critical part of the internalization process, we used the PathHunter® to compare arrestin recruitment with internalization. In CHO hMOP cells, UFP-505 induced a concentration-dependent recruitment of β-arrestin to the μ receptor with a pEC 50 of 6.91 ( Figure 4A ), which was not significantly different to the pEC 50 of morphine (6.75). However, at 10 μM, morphine showed significantly lower E max than UFP-505, EM1 and fentanyl, whereas EM1 and fentanyl showed significantly higher E max than UFP-505. For the δ receptors, although DPDPE produced a concentration-dependent recruitment of β-arrestin upon receptor activation, UFP-505 did not ( Figure 4B ). We do not know the receptor density of the cells used in this assay as they were provided ready-to-go by the assay manufacturer.
In vitro characterization of the double-expression system
All of our in vitro work so far had been with a single expression system, so in order to mimic the in vivo situation in a simple system, we produced CHO cells with double expression of μ and δ receptors. Our selected monoclonal CHO hMOP/hDOP batch had a B max of 672 ± 34 and 159 ± 32 fmol·mg
À1
(mean ± SEM) for the μ and δ receptors respectively, using tritiated naltrindole ( Pharmacology of bifunctional opioid UFP-505 in saturation binding assays. This gave a μ:δ receptor ratio of 4:1. In addition, full saturation curves with the non-selective ligand [
3 H]-DPN confirmed the overall expression levels of both types of opioid receptors to be 851 ± 45 fmol·mg À1 as shown in Figure 5A ; the numerical sum of individual μ receptors (672) and δ receptors (159) Figure 5B ). The 'overall' binding affinity (pK i ) of UFP-505 in CHO hMOP/hDOP membranes was 7.70 ± 0.16 (n = 5), whereas the binding affinities for the respective reference ligands were to be 7.53 ± 0.10 (EM1), 7.87 ± 0.07 (naltrindole) and 7.75 ± 0.11 (morphine) respectively.
The capacity of UFP-505 to induce receptor internalization in the mixed μ and δ receptor population was then studied. UFP-505 induced~62% opioid receptor internalization (μ and δ ), significantly higher than morphine which did not induce significant internalization compared to control ( Figure 5C ). Pretreatment of DPDPE and EM1 produced~27 and~43% internalization respectively.
In the GTPγ 35 S assay, pretreatment of CHO hMOP/hDOP cells with EM1 or UFP-505 produced a significant reduction in the efficacy (E max ) of both ligands, without change in potency (pEC 50 ) ( Figure 6 ). The next step from a simple double expression system was to examine behaviour in vivo in standard antinociceptive assays acutely and, after chronic treatment, to assess tolerance.
In vivo characterization of UFP-505
TF test. UFP-505 produced a time-and dose-dependent antinociceptive response (Figure 7 ). Treatment with 10 and 50 but not 1 and 3 nmol UFP-505 produced a significant response. Furthermore, animals treated with 50 nmol UFP-505 reached and retained the cut-off time from the first sampling point (15 min) throughout the study to 120 min ( Figure 7A ). Morphine, injected i.t., in a dose of 10 nmol produced a similar antinociceptive profile to UFP-505 (10 nmol), which was not significantly different from 15 min until 90 min after injection. However, morphine antinociception was significantly reduced at 120 min after injection. An analysis of UFP-505 dose-response curves for latency at 120 min after administration and AUC (s·min) from Figure 7A are shown in Figure 7B . to the 30 and 10 nmol doses at 15 and 30 min ( Figure 8A ). Based on the mechanical threshold at 15 min, a crude ED 50 of~9 nmol can be estimated, similar to that obtained in the TF assay. In Figure 8B , the effects of daily administration of 3 nmol morphine and 10 nmol UFP-505 are shown; based on previous data (Micheli et al., 2015) , this dose of morphine is equi-effective to 10 nmol UFP-505 in an acute setting. By days 6-7, animals were tolerant to both morphine and UFP-505. There were no differences in the time course for induction of tolerance between the two ligands.
Rotarod test. In both acute tests using the animals from the PP animal group, there were no significant effects on performance at doses up to and including 10 nmol. At 30 nmol UFP-505, there was marked impairment of locomotor activity of the posterior paws; at the 15 min time point, the cut-off of six falls was reached (Table 1) .
Ex vivo study of neuronal tissue from treated animals in the TF study
We had the opportunity to collect and analyse the neuronal tissue from the treated rats in order to assess the receptor turnover in vivo and to compare the produced data with our in vitro data. Membrane from lysates of rat neuronal tissue (cortex and spinal cord) of acutely treated animals (UFP-505, morphine and saline) was used for 
Figure 6
Receptor desensitization in CHO hMOP/hDOP cells. Ligand-mediated GTPγ 35 S binding measured in membranes prepared from CHO hMOP/hDOP cells after pretreatment of CHO hMOP/hDOP cells with 10 μM EM-1 or 10 μΜ UFP-505 (control; no pretreatment) for 1 h and following a challenge with a range of concentrations of (A) EM-1 or (B) UFP-505. Data are expressed as mean ± SEM (n = 5). There were no significant differences in the pEC 50 of either EM-1 or UFP-505 comparing the pretreatment values with the respective control. Pretreatment E max values for both EM-1 and UFP-505 were lower than control; *P < 0.05; one-way ANOVA with Bonferroni test. (1 nmol n = 4; 3 nmol, n = 7; 10 nmol, n = 7; 50 nmol, n = 4) and morphine 10 nmol (n = 7) in rats using a TF assay (15 s cut-off time). Measurements were taken from 15 to 120 min after a single drug administration. All groups had originally n = 8, but due to a technical failure in catheter stabilization, only the animals described here successfully completed the experiments. The antinociception recorded at 120 min after administration for UFP-505 (10 nmol; n = 7) was greater than that of morphine (10 nmol). *P < 0.05, significantly different from saline; #P,0.05, significantly different from morphine; Student's t-test. (B) Dose-response curves for UFP-505 produced from the curves in (A), for latency after 120 min of drug administration (expressing antinociception after 2 h) and the corresponding AUC (in s·min, expressing total antinociception). The antinociceptive potency of UFP-505, as deduced from the 120 min latency curve had pEC 50 8.20 ± 0.05 (EC 50 6.27 nmol), whereas the potency from the AUC curve had pEC 50 8.19 ± 0.18 (EC 50 6.38 nmol).
labelling the μ and δ receptors with
Nt, in a series of independent binding assays with saturating concentrations of radioligand. Processing of these membranes was based on the same procedures as used for the membranes from cell lysates. Receptor density values (B max ) were calculated, and density changes were expressed in % difference from saline-treated animals, as shown in Table 2 . Administration of morphine did not induce any changes in receptor density in the frontal cortex for both μ and δ receptors. In contrast, treatment with UFP-505 induced a loss of cell surface μ and δ receptors in this tissue, compared to morphine-treated and untreated membranes. Additionally, for the spinal cord samples, the effect of UFP-505 and morphine on cell surface receptor numbers was similar (internalization of μ receptors : 44.7%, of δ receptors: 43.1%). A reduction in density of both receptors was observed in the UFP-505-treated samples compared to the expression of the respective receptors in the morphine and untreated samples ( Table 1 ). The ineffectiveness of morphine to internalize the μ receptors agrees with other studies (Whistler and von Zastrow, 1998; Zhang et al., 1998; Bohn et al., 2004) and with the rest of internalization data presented later here. Additionally, the cortex and spinal cord tissue from treated and non-treated animals were pooled in two discrete groups and processed as two batches to determine opioid receptor mRNA expression by RT-qPCR (expressed as ΔC tcycle threshold difference values compared to GAPDH; Table 1 Effect on motor coordination evoked by acute spinal administration of UFP-505 shown in Supporting Information Table S1 ). In acutely morphine-treated animals, variable changes in opioid receptor mRNA levels were observed for all opioid receptors across all tissues examined. One interesting change that stood out is that acute i.t. morphine and UFP-505-treated animals showed up-regulation of the mRNA for the μ receptors in the spinal cord, but only morphine-treated animals showed simultaneous up-regulation of the δ receptors. The data with morphine align with findings from other studies showing that exposure to morphine increased the surface expression of δ receptors in cultured cortical neurons and in neurons in the dorsal horn of the spinal cord in vivo (Cahill et al., 2001; Morinville et al., 2003) , although these findings were based on a 48 h exposure to morphine. Furthermore, in the frontal cortex, only the κ receptor mRNA levels were shown to up-regulate in morphine-treated animals. In the rest of the cortex, only the mRNA levels for the δ receptors were significantly down-regulated in both treatment groups. Finally, in the same tissues, levels of the mRNA for the NOP receptor were down-regulated in both treatment groups.
Discussion
Bifunctional opioids have long been studied in opioid pharmacology, either for exploring the relationship between different receptor types or aiming to produce opioid ligands with reduced adverse effects (Dietis et al., 2009; Schiller, 2010) . In this study, we show that UFP-505 behaves as a full agonist at the μ receptor and displays a variable expression-dependent efficacy at the δ receptor. This bifunctional compound produces antinociception in rats after i.t. administration.
Partial agonism depends on expression levels
At intermediate levels of expression of δ receptors and in an unamplified system, UFP-505 behaves as a competitive δ receptor antagonist (Dietis et al., 2012) , and at very high expression levels in an amplified system, UFP-505 can display a partial agonist activity. This behaviour agrees with our previous observations that partial agonist behaviour is largely depended on receptor expression levels (McDonald et al., 2003) . Indeed, in CHO hDOP cells, we were able to unmask low efficacy in a GTPγ 35 S assay (0.28 relative to DPDPE; unamplified, with δ receptor levels at~2 pmol·mg À1 protein) and in cAMP assay (amplified, with δ receptor levels at~1 pmol·mg À1 protein). No activity was shown by UFP-505 in the commercial arrestin assay (unamplified, with δ receptor expression levels unknown) whereas full agonist activity was shown for the loss of cell surface receptors (amplified, with δ receptor levels at~1 pmol·mg À1 protein).
Reduced radioligand binding translates to true loss of cell surface receptors
The accuracy of receptor expression determined by radioligand labelling is sensitive to 'sticky' ligands that remain bound to receptors, as they may reduce radioligand binding that can be misinterpreted as reduced receptor density. In our standard experimental protocol, we use extensive washing when using natural peptide ligands and radiolabelling (Hashimoto et al., 2002) . However, we also constructed a full saturation curve to [ 3 H]DPN in both μ and δ receptor cell lines, in order to provide evidence of effective wash-off, with the resulting K d of the radioligand being unaffected, indicating that there was no residual desensitizing challenge present at the receptor. We therefore conclude that the reduction in radioligand binding represents a true loss of cell surface receptors. In addition, we show loss of cell surface receptors in well-washed membranes from tissues extracted from whole animals.
Arrestin recruitment and receptor internalization
Control of post-receptor signalling lies in a coordinated interplay between receptor activation and loss of cell surface receptors by endocytosis (internalization). The recruitment of β-arrestin-2 plays a central role to the internalization of opioid receptors and other GPCRs (Zuo, 2005) . Early studies showed that morphine fails to internalize the membrane μ receptors (Keith et al., 1996) , and stimulation of μ receptor endocytosis by enhanced β-arrestin-2 can counteract the development of morphine tolerance (Koch et al., 2005) . Nevertheless, the involvement of β-arrestin-2 in morphine tolerance is more complicated than a straightforward linear effect, the reduction of cellular levels of β-arrestin-2 may also attenuate morphine tolerance (Yang et al., 2011; Wang et al., 2016) . In our assay, activation of μ receptors caused the recruitment of β-arrestin-2 with a rank order of E max EM1 > fentanyl > UFP-505 > morphine. UFP-505 was able to recruit β-arrestin-2 significantly more than morphine. Despite UFP-505 being a low-efficacy partial agonist at δ receptors and able to induce internalization, the ligand did not show any significant recruitment of β-arrestin-2. We do not know the level of δ receptor expression in this commercial assay, so it is possible that the lack of a partial agonism response by UFP-505 in the δ receptor-expressing cells of this assay could be due to the low receptor expression in this system, unmasked only at higher levels. On the other hand, there are mechanisms of receptor internalization that are independent of β-arrestin-2 (Van Koppen and Jakobs, 2004; Bradbury et al., 2009) , and whether these mechanisms are part of UFP-505 activity is unknown. In addition, the ability of a ligand to resensitize μ receptors and to promote recycling is also an important factor for its tolerance profile (Dang and Christie, 2012) , an aspect for UFP-505 that needs to be clarified. In essence, UFP-505 was shown to be a ligand unlike morphine in its ability to induce internalization of μ receptors and therefore seemed to have the potential to produce reduced analgesic tolerance compared to morphine.
In vitro studies with a double expression system
We aimed to simulate the in vivo situation, where μ and δ receptors are co-expressed, by producing a stable recombinant CHO hMOP/DOP double expression system. In this system, morphine failed to internalize both receptors and UFP-505 was more effective than EM1 in internalizing μ receptors, data that are consistent with the single μ receptor expression system. There was a reduced ability of DPDPE to internalize δ receptors, and while it is tempting to suggest that this may potentially result from the dimer, it could be simply a result of the relatively lower density of δ receptors compared with μ receptors, in this cell line. The μ and δ receptors have been shown to co-localize in vivo (Wang et al., 2005) , and their constitutive dimerization plays a functional role in disease and ligand pharmacology Yekkirala et al., 2012) . Doubleexpression recombinant systems have been previously used and showed that the potency of opioids may differentiate compared to single-opioid receptor expression cell lines (Yekkirala et al., 2010; Yekkirala et al., 2012) . Moreover, the response of these opioids in the μ / δ co-expression system has been shown to be reversed with naltrindole, suggesting a functional interaction between the two receptors. This is in agreement with Waldhoer et al. (2005) who showed that heterodimer activation (by 6-guanidinonaltrindole) was tissue-specific and only occurred at the level of the spinal cord. Collectively, these data suggest that δ receptor blockade can reduce the efficacy of morphine when μ receptors are coexpressed, which agrees with the premise of our study that, as δ receptor antagonism reduces morphine tolerance, it may explain why UFP-505 has reduced tolerance liability. In the longer term, if δ receptor antagonism reduces μ receptor signalling, then it is possible that this could have a 'protective effect' on μ receptors, reducing their ability to desensitize. More importantly, there is evidence to suggest that receptor dimer numbers do change in chronic pain (Costantino et al., 2012) , supporting the claims of a vital physiological role of these receptor dimers in disease. Certainly, UFP-505 is able to produce internalization and does not behave like morphine in this respect. In our double-expression system, the potency of UFP-505 is greater by fivefold than in the single μ receptor expression system, suggesting that our bifunctional ligand is interacting with a functional μ-δ receptor heterodimer. Clearly, further experimentation with tagged opioid receptors and UFP-505 are required.
In vivo experiments
Acute i.t. injection of UFP-505 produced a robust antinociceptive response in the TF assay with potency (ED 50 ) of 7 nmol and 10 nmol of UFP-505 was as antinociceptive as 10 nmol of morphine. More importantly, our data show that UFP-505 produced prolonged antinociception that persisted more than 120 min after acute administration, compared with the time course of morphine antinociception. Similar data were obtained in the PP test (using a different catheterization strategy) with ED 50 for UFP-505 of~9 nmol. These data confirm for the first time the presumption of a strong antinociceptive dose-dependent effect of UFP-505 as a μ receptor ligand with agonist activity. Morphine tolerance has been consistently observed in rats after 3 days with i.t. treatment (Granados-Soto et al., 2000; Paul et al., 2017) or 5 days with s.c (Goodchild et al., 2009) or i.p treatment (Chen et al., 2008) . We confirmed these findings for morphine with our long-term testing using the PP test. Bifunctional ligands with a μ receptor agonist and δ receptor antagonist profile have been shown to have reduced tolerance profile (Mosberg et al., 2014) , and therefore, we expected that UFP-505 would show a similar profile in our long-term tests of paw withdrawal, given its pharmacological profile in vitro and its analgesic efficacy in vivo. However, to our surprise, UFP-505 produced a tolerance profile that was not significantly different from that of morphine in our model.
Although we have no data that will offer a mechanistic explanation of UFP-505's tolerance profile, there are two factors that could explain this unexpected result. The first is the model in which antinociception is assessed. Different pain models, such as TF, hot-plate, PP, warm water tailwithdrawal, capsaicin administration and acetic acid writhing) utilize different types of nociceptive stimuli (electrical, thermal, mechanical and chemical) that require the involvement of a mixed variety of neuronal processes (Le Bars et al., 2001) . Given the complex molecular changes that occur during long-term exposure of opioids and the stimuli differences between antinociceptive models, it is possible that the development of nociceptive tolerance is model-sensitive. Another potential contributor to the tolerance profile of UFP-505 is the dose and method of administration used. Some recent studies have suggested a dose dependence for the induction of opioid tolerance (Pawar et al., 2007; Madia et al., 2009) , which increases the difficulty of efficiently comparing data from studies that use different opioid doses and routes of administration. A simpler explanation could be that the observed residual agonist activity at δ receptors may become important in producing tolerance. Studies with a pure δ receptor antagonist would help to settle this point.
Nevertheless, the profile of tolerance liability in opioids that possess a bi-or multi-functional activity profile is not new. A characteristic example of such a ligand is buprenorphine, a well-known and fully characterized complex opioid that has been studied for more than 40 years (Lutfy and Cowan, 2004) . Although buprenorphine is a μ receptor partial agonist, and an antagonist at δ and κ receptors (Huang et al., 2001) , its tolerance profile is somewhat similar to morphine (Paronis and Bergman, 2011) . Nevertheless, the pharmacokinetic profile and a lack of a ceiling effect in the clinical setting are seen as an advantage (Louis, 2006; Khanna and Pillarisetti, 2015) .
The main aim of the study was to fully characterize a promising bifunctional ligand (based on earlier data) and to provide insights on the potential relationship between in vitro and in vivo activity. Full characterization of a bifunctional opioid with multiple in vitro/ex vivo/in vivo assays is important but not often performed. Our data present a continuum from basic pharmacology to antinociceptive actions in vivo. Specifically, this study of UFP-505 (in vitro and in vivo) offers invaluable information on the pharmacological properties that bifunctional opioids may present. Unfortunately, the lack of antinociceptive efficacy of UFP-505 via an additional subcutaneous route (see Supporting Information Figure S1 ) may preclude further development. Nevertheless, the insights gained from studying UFP-505 are of value in the search for newer opioid-like compounds with increased antinociceptive efficacy and reduced liability for tolerance.
